Cancer Family
Mesothelial Neoplasm
CI-CAN-00000028Explore in graph →
Non-malignant108 active trials4 approved drugs13 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000028Explore in graph →
Clinical trials
521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04106973 | Mesothelioma Early Detection by VOCs(MED-VOC) | terminated | — | 12 | Henry Ford Health SystemOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03075527 |
| A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma |
| terminated |
| Phase 2 |
| 19 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Jul 16, 2026 |
| clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | terminated | Phase 1 | 19 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Jul 7, 2026 | clinicaltrials |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 | 41 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 1, 2026 | clinicaltrials |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03684486 | Rehabilitation by Effort for Patients With Advanced Bronchial Cancer(RehabKBP) | terminated | N/A | 19 | University Hospital, ToulouseOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT01851395 | Rapid Autopsy and Procurement of Cancer Tissue | terminated | — | 32 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04166734 | Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma(MESO-PRIME) | terminated | Phase 1 | 5 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT04914897 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | terminated | Phase 2 | 106 | SanofiINDUSTRY | 11 | Oct 2, 2025 | clinicaltrials |
| NCT02863055 | Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma(NEMO) | terminated | Phase 2 | 37 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Sep 19, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT02613299 | Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma | terminated | — | 5 | Mayo ClinicOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients(TOASTIT) | terminated | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT02648763 | Staging Procedures to Diagnose Malignant Pleural Mesothelioma | terminated | — | 33 | Mayo ClinicOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05228015 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors | terminated | Phase 1 | 67 | Ikena OncologyINDUSTRY | 3 | Nov 18, 2024 | clinicaltrials |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT02748798 | Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders | terminated | Early Phase 1 | 10 | Thunder Bay Regional Health Research InstituteOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT02707666 | A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma | terminated | Phase 1 | 7 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 49 | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03319537 | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | terminated | Phase 1 / Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT03502746 | Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma | terminated | Phase 2 | 34 | Arkadiusz Z. Dudek, MDOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT01898156 | Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer | terminated | Phase 1 / Phase 2 | 37 | Kyowa Kirin Korea Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | terminated | Phase 2 | 35 | Verastem, Inc.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03393858 | Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma | terminated | Phase 1 / Phase 2 | 10 | Capital Medical UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04840615 | Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma | terminated | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT02688166 | Cardiac MRI Biomarker Testing (GCC 1618) | terminated | — | 6 | University of Maryland, BaltimoreOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT00637624 | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy(NAC-PNP) | terminated | N/A | 69 | Rijnstate HospitalOTHER | 1 | Aug 25, 2022 | clinicaltrials |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | terminated | Phase 1 | 9 | Augusta UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT02385812 | Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma | terminated | Phase 2 | 200 | University of CalgaryOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT03655821 | Dose Individualization of Pemetrexed - IMPROVE-II(IMPROVE-II) | terminated | Phase 4 | 81 | Radboud University Medical CenterOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02838745 | Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM | terminated | Phase 1 | 7 | Baylor College of MedicineOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02464904 | Intrapleural Cryotherapy for Malignant Pleural Mesothelioma | terminated | N/A | 17 | Mayo ClinicOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT03644550 | Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Dec 2, 2021 | clinicaltrials |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | terminated | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | terminated | Phase 1 | 14 | MaxCyte, Inc.INDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT00003508 | Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma | terminated | Phase 2 | 8 | Burzynski Research InstituteOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT00859495 | Trimodal Lung-Sparing Treatment of Pleural Mesothelioma | terminated | Phase 2 | 9 | Columbia UniversityOTHER | 1 | Aug 25, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 10, 2026source: clinicaltrials